Go to the content anchor

MOST Germination Program: Taiwan-Denmark International Technical Cooperation of rapid COVID-19 diagnostic test in 12 minutes April 8, 2020


Taiwan-Denmark international technical cooperation, the MOST supports new Start-up.

Since 2010, the MOST has promoted the "Germination Program", focusing on the “From Academics to Market:Transform Research to Innovation”. Innovation economy becomes one of the major focuses of the government sector in Taiwan. Currently the Ministry of Science and Technology (MOST) founded about 14,000 research programs for academic units per year.

BluSense Diagnostics has established in 2014.The technical cooperation between Taiwan and Denmark. After being subsidized by the MOST, the main shareholders are TaiAn Technologies Corp. and Quanta Storage Inc.. BluSense 's biotech R & D base is located in Copenhagen, Denmark, while the hardware and software center and equipment production are located in Taoyuan, Taiwan. They has an international team, combined with the advantages of Taiwan's IT industry, based on Blu-ray disc drive, designed and developed BluBox, a portable medical detection platform, and a micro-channel biological detection disc ViroTrack, which is very convenient to carry and operate, suitable for being applied used in airports, ports and other first-line epidemic prevention places.

BluSense overcomes the difficulties of the existing detection system and develops products with high accuracy, convenient portability and easy operation. Only one drop of blood sample (30 μl) is required from the test subject, and no pretreatment such as centrifugation is required. Quantitative, high sensitivity and specificity test results can be obtained within 12 minutes.

Rapid COVID-19 diagnostic test

BluSense focuses on the detection of infectious diseases. Its Dengue Acute System has obtained the EU CE and has being sold since then. At the time of COVID-19, we need immediate testing products. BluSense completed the development of COVID-19 serology test cartridge (ViroTrack COVID-19 IgM / IgG) in March 2020 with the support of the TEN-CHEN MEDICAL GROUP advice to help the detection system to continuously optimized.

Last week , BluSense has a preliminary clinical verification was performed at Hvidovre hospital, Denmark , with a sensitivity of up to 90%. This exciting result and the news was disclosed by an interview with the famous Danish news station (DR).

Get results in 12 minutes, reducing the heavy burden on the medical laboratory

BluSense can be focus on COVID-19 serology test:

(1).Community trace-back and detection of suspected asymptomatic patients

PCR is the main detection method for COVID-19 at this moment. PCR requires professional operation and 4 hours to obtain results, and sometimes requires repeated testing, which causes a heavy burden on the medical laboratory. BluSense 's rapid and accurate detection technology can assist in performing a large number of community backtracking, diagnosis of asymptomatic patients and screening travel history personnel, greatly reducing the pressure on medical inspection personnel.

(2). Confirm whether the patient discharge

At this stage, to confirm whether the patient can be discharged from the hospital, three PCR tests will be negative. BluSense 's COVID-19 serology test test can provide quantitative test results, understand the changes of IgG and IgM antibodies in patients, and can be used as a reference for whether it is suitable for discharge.

BluSense has innovative technology, professional R & D team and experience in cooperation with international health organizations. When a new infectious disease , it has the ability to develop corresponding rapid detection products in a short time.In 2016, Zika broke out everywhere, especially in Central and South America. At that time, BluSense stood out with a high degree of competition from international manufacturers (the selection rate was 2%), won the USAID-USAID-Combating Zika R & D bonus, and completed product development and certification within the expected time. In addition, it also received funding for the European Union ’s Horizon 2020 SME Phase II in 2018. This funding rate was only 3% in Europe. It also represents the EU ’s recognition that BluSense has global Start-up companies with innovation and competitiveness. When all countries face the test of the COVID-19, I hope BluSense can become the light of Taiwan and do its part for the world.



Media Contact

Jessie Sun,

Executive Vice President, BluSense BioTech Co. Ltd.

TEL: +886-3-318-5851  



Yue-Mei Lin,

Assistant Researcher

Department of Academia-Industry Collaboration and Science Park Affairs,MOST
TEL: +886-2-2737-7240

Last Modified : 2020/04/09